Oncology News and Research

RSS

Oncology, meaning bulk, mass, or tumor, and the suffix ''-logy'', meaning "study of") is a branch of medicine that deals with tumors (cancer). A medical professional who practices oncology is an ''oncologist''.

Pfizer-FRSQ Innovation Fund supports genetic study of inflammatory bowel disease and cancer

The first two research projects supported by the Pfizer-FRSQ Innovation Fund will investigate differences in the genetic code for inflammatory bowel disease and metastatic colorectal cancer. This research could lead to improved diagnosis and the development of individualized treatments for these diseases. These innovative projects are marshalling multidisciplinary teams of seasoned researchers from major Quebec research institutions.

8 Oct 2009

APP Pharmaceuticals receives FDA approval to market Sumatriptan Succinate Injection

APP Pharmaceuticals, Inc., a wholly owned subsidiary of Fresenius Kabi Pharmaceuticals Holding, Inc., (NASDAQ: APCVZ) announced today that it has received approval from the U.S. Food and Drug Administration (FDA) to market Sumatriptan Succinate Injection, USP, in two dosage strengths.

8 Oct 2009

Epizyme raises $32 million through its Series B financing

Epizyme, Inc., a biopharmaceutical company translating key discoveries in the field of epigenetics into novel pharmaceutical agents, announced today the closing of a $32 million Series B financing led by new investor Bay City Capital (BCC).

8 Oct 2009

Ethnicity plays a significant role in non-small cell lung cancer genetics: Study

Clinical research out of University Hospitals Case Medical Center has found that African Americans with a common form of lung cancer have a lower frequency of drug-sensitizing genetic mutations, which may impact response to new cancer-fighting drugs.

8 Oct 2009

Entest BioMedical applies for Phase II grant from National Cancer Institute

Entest BioMedical, Inc. a majority owned subsidiary of Bio-Matrix Scientific Group, Inc. announced today that it has applied for an Exploratory/Development Phase II grant from the National Cancer Institute (NCI).

8 Oct 2009

NIH grants over $3.8 million to Asuragen

Asuragen, Inc. announced today that it has received over $3.8 million in new grant funding for 2009 from the Small Business Innovative Research (SBIR), Small Business Technology Transfer (STTR), and American Recovery and Reinvestment Act (ARRA) funded initiatives of the National Institutes of Health (NIH) to further its development of molecular diagnostics for oncology and genetic disease.

8 Oct 2009

Amarillo Biosciences, Intas Pharmaceuticals enter strategic partnership to combat influenza in India

Amarillo Biosciences, Inc. today announced that it has agreed to a strategic partnership with Intas Pharmaceuticals Limited (Intas), one of the top 20 pharmaceutical companies in India, whereby Intas will sponsor clinical trials of ABI's orally administered interferon-alpha lozenges in order to combat influenza. Intas will pay ABI a royalty on net sales after marketing approval is obtained in India.

8 Oct 2009

Genomic Health to present study results of Oncotype DX multi-gene expression test

Genomic Health, Inc. today announced that the company will present results from two studies at the American Society of Clinical Oncology (ASCO) 2009 Breast Cancer Symposium, taking place October 8 through October 10 at the San Francisco Marriott in San Francisco, California.

8 Oct 2009

NCI awards $11.5 million grant to UAB for cervical cancer research

The University of Alabama at Birmingham (UAB) Comprehensive Cancer Center has won an $11.5 million grant from the National Cancer Institute (NCI) to explore groundbreaking cervical cancer research, prevention and treatment.

8 Oct 2009

Relypsa commences patient enrollment in Phase 2b clinical trial of RLY5016 for treating hyperkalemia

Relypsa, Inc., today announced the initiation of patient enrollment in the PEARL-HF study, a Phase 2b clinical trial of the company’s lead compound, RLY5016. A novel potassium binder designed for chronic use, RLY5016 is being evaluated in the prevention and treatment of hyperkalemia, for which there are no current satisfactory treatments.

7 Oct 2009

New lung cancer pathways discovered using computer modeling

Using computer modeling, the Translational Genomics Research Institute and Scottsdale Healthcare have discovered lung cancer 'pathways' that could become targets for new drugs, according to a scientific paper published online today by the Journal of Thoracic Oncology.

7 Oct 2009

Uterine artery embolization proves to be better than laparoscopic occlusion of uterine arteries in treating fibroids

BioSphere Medical, Inc. – the pioneer in the use of bioengineered microspheres to treat uterine fibroids, hypervascularized tumors and vascular malformations by a minimally invasive, image-guided medical procedure called embolotherapy – reports the publication of a study in the October 2009 issue of the Journal of Vascular Interventional Radiology in which the authors conclude that uterine artery embolization (UAE) compares favorably to laparoscopic occlusion of uterine arteries in the treatment of uterine leiomyomas (fibroids) in cases where hysterectomy or myomectomy are not options.

7 Oct 2009

Panel Intelligence expands patient focused market research service

Panel Intelligence, LLC, is pleased to announce expanded capabilities for patient focused market research. For 10 years, Panel Intelligence has provided actionable market intelligence in the form of primary research from clinicians and other healthcare professionals.

7 Oct 2009

GlobeImmune to present an abstract of GI-5005 drug at AASLD's annual meeting

GlobeImmune Inc. today announced that a late breaking abstract related to GI-5005, its investigational hepatitis C virus (HCV) product candidate, has been accepted for presentation at the 60th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD), which will take place Oct. 31 through Nov. 4, 2009, in Boston, Mass.

7 Oct 2009

Daily doses of imatinib mesylate double survival rates in Ph+ ALL affected children

Results of a phase two clinical trial published October 5th in the Journal of Clinical Oncology show that adding continuous daily doses of a targeted drug called imatinib mesylate to regular chemotherapy more than doubled three-year survival rates for children with a high risk type of blood cancer called Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL).

7 Oct 2009

Physical activity during adolescence decreases risk of glioma

While little is known about the causes of glioma, researchers at the National Cancer Institute have found that this rare but often deadly form of brain cancer may be linked to early life physical activity and height.

7 Oct 2009

Combination of leukemia and breast cancer drugs inhibits cancer progression

When breast cancer spreads or metastasizes, it crashes through the body's protective fences. The disease becomes fatal when it travels outside the mammary ducts, enters the bloodstream and spreads to the bones, liver or brain.

7 Oct 2009

Stereotactic Radiosurgery for metastatic brain tumors reduces risks of learning and memory problems

Cancer patients who receive stereotactic radiosurgery (SRS) and whole brain radiation therapy (WBRT) for the treatment of metastatic brain tumors have more than twice the risk of developing learning and memory problems than those treated with SRS alone, according to researchers at The University of Texas M. D. Anderson Cancer Center.

7 Oct 2009

Scientists create new technology to improve detection of leukemia cells in bone marrow

Scientists have created a viable technology to improve the detection of leukemia cells in bone marrow.

7 Oct 2009

$16 million federal stimulus funds establish Seattle as national hub for cancer research

Researchers at Fred Hutchinson Cancer Research Center, Group Health Research Institute and the University of Washington schools of Public Health and Pharmacy have been selected to lead four projects backed by approximately $16 million in federal stimulus funding for comparative-effectiveness research in cancer.

7 Oct 2009

Oncology News and Research

Further Reading

Pfizer-FRSQ Innovation Fund supports genetic study of inflammatory bowel disease and cancer

APP Pharmaceuticals receives FDA approval to market Sumatriptan Succinate Injection

Epizyme raises $32 million through its Series B financing

Ethnicity plays a significant role in non-small cell lung cancer genetics: Study

Entest BioMedical applies for Phase II grant from National Cancer Institute

NIH grants over $3.8 million to Asuragen

Amarillo Biosciences, Intas Pharmaceuticals enter strategic partnership to combat influenza in India

Genomic Health to present study results of Oncotype DX multi-gene expression test

NCI awards $11.5 million grant to UAB for cervical cancer research

Relypsa commences patient enrollment in Phase 2b clinical trial of RLY5016 for treating hyperkalemia

New lung cancer pathways discovered using computer modeling

Uterine artery embolization proves to be better than laparoscopic occlusion of uterine arteries in treating fibroids

Panel Intelligence expands patient focused market research service

GlobeImmune to present an abstract of GI-5005 drug at AASLD's annual meeting

Daily doses of imatinib mesylate double survival rates in Ph+ ALL affected children

Physical activity during adolescence decreases risk of glioma

Combination of leukemia and breast cancer drugs inhibits cancer progression

Stereotactic Radiosurgery for metastatic brain tumors reduces risks of learning and memory problems

Scientists create new technology to improve detection of leukemia cells in bone marrow

$16 million federal stimulus funds establish Seattle as national hub for cancer research

Event guide: 10th CAR-TCR Summit eBook

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News